Weimin Mao

928 total citations
34 papers, 547 citations indexed

About

Weimin Mao is a scholar working on Pulmonary and Respiratory Medicine, Molecular Biology and Oncology. According to data from OpenAlex, Weimin Mao has authored 34 papers receiving a total of 547 indexed citations (citations by other indexed papers that have themselves been cited), including 15 papers in Pulmonary and Respiratory Medicine, 14 papers in Molecular Biology and 12 papers in Oncology. Recurrent topics in Weimin Mao's work include Esophageal Cancer Research and Treatment (10 papers), Lung Cancer Treatments and Mutations (10 papers) and Cancer-related gene regulation (7 papers). Weimin Mao is often cited by papers focused on Esophageal Cancer Research and Treatment (10 papers), Lung Cancer Treatments and Mutations (10 papers) and Cancer-related gene regulation (7 papers). Weimin Mao collaborates with scholars based in China, Poland and Singapore. Weimin Mao's co-authors include Xiaoling Xu, Wei Hu, Qian Song, Min Zhang, Zhiwen Pan, Zhi‐Qiang Ling, Xiaohong Xu, Lei Gong, Zhiyu Huang and Luo Fang and has published in prestigious journals such as Journal of Clinical Oncology, PLoS ONE and Clinical Cancer Research.

In The Last Decade

Weimin Mao

31 papers receiving 543 citations

Peers

Countries citing papers authored by Weimin Mao

Since Specialization

Citations

This map shows the geographic impact of Weimin Mao's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Weimin Mao with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Weimin Mao more than expected).

Fields of papers citing papers by Weimin Mao

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Weimin Mao. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Weimin Mao. The network helps show where Weimin Mao may publish in the future.

Co-authorship network of co-authors of Weimin Mao

This figure shows the co-authorship network connecting the top 25 collaborators of Weimin Mao. A scholar is included among the top collaborators of Weimin Mao based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Weimin Mao. Weimin Mao is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Outcomes of neoadjuvant immunochemotherapy and neoadjuvant chemoradiotherapy in patients with locally advanced esophageal squamous cell carcinoma 2025 ·Surgery ·(unknown), Yueyao Du, Liwei Xu, Youhua Jiang, Qixun Chen, Jian Zeng, Lei Cai, Yujin Xu, Xiaojiang Sun, Weimin Mao, Changchun Wang	0
2	Plasma Small Extracellular Vesicle microRNAs as Non-Invasive Biomarkers for Lung Cancer Detection 2025 ·International Journal of Nanomedicine ·Qiao‐Li Lv, (unknown), (unknown), Dongyu Liu, Xiaoling Xiong, (unknown), Yan Feng, Dadong Zhang, (unknown), Weimin Mao	0
3	Analysis of SPARC and TUBB3 as predictors for prognosis in esophageal squamous cell carcinoma receiving nab-paclitaxel plus cisplatin neoadjuvant chemotherapy: a prospective study 2019 ·Cancer Chemotherapy and Pharmacology ·Lei Gong, Weimin Mao, Qixun Chen, Youhua Jiang, Yun Fan	13
4	<p>Evaluation of therapeutic efficacy with CytoSorter<sup>®</sup>, circulating tumor cell–capture system in patients with locally advanced head and neck squamous cell carcinoma</p> 2019 ·Cancer Management and Research ·Weihui Zheng, (unknown), Liang Guo, Shengye Wang, Meiyu Fang, Weimin Mao, Jianlin Lou	13
5	Cell-Cycle and DNA-Damage Response Pathway Is Involved in Leptomeningeal Metastasis of Non–Small Cell Lung Cancer 2017 ·Clinical Cancer Research ·Yun Fan, Xuehua Zhu, Yan Xu, Xuesong Lu, Yanjun Xu, Mengzhao Wang, Haiyan Xu, (unknown), Xin Ye, Luo Fang, Zhiyu Huang, Lei Gong, Hongyang Lu, Weimin Mao, Min Hu	45
6	Immune checkpoint inhibitors in lung cancer: current status and future directions 2017 ·Chinese Clinical Oncology ·Yun Fan, Weimin Mao	7
7	O6-methyl-guanine-DNA methyltransferase methylation and IDH1/2 mutation in small cell lung cancer 2017 ·Experimental and Therapeutic Medicine ·Hongyang Lu, Jing Qin, Haimiao Xu, Na Han, Fajun Xie, Weimin Mao	8
8	Neoadjuvant chemoradiotherapy or chemotherapy followed by surgery is superior to that followed by definitive chemoradiation or radiotherapy in stage IIIA (N2) nonsmall-cell lung cancer: a meta-analysis and system review 2016 ·OncoTargets and Therapy ·Weimin Mao, Xiaoling Xu, Wei Chen, (unknown), (unknown)	11
9	Combined nimotuzumab with chemoradiotherapy in patients with locally advanced or metastatic esophageal squamous cell carcinoma: A retrospective study 2016 ·Journal of Cancer Research and Therapeutics ·(unknown), (unknown), (unknown), Guan Liu, (unknown), (unknown), Weimin Mao	8
10	A Novel Inflammation-Based Prognostic Score, the C-Reactive Protein/Albumin Ratio Predicts the Prognosis of Patients with Operable Esophageal Squamous Cell Carcinoma 2015 ·PLoS ONE ·Xiaoling Xu, (unknown), Wei Hu, Qian Song, Weimin Mao	115
11	A phase II study of icotinib and whole-brain radiotherapy in Chinese patients with brain metastases from non-small cell lung cancer 2015 ·Cancer Chemotherapy and Pharmacology ·Yun Fan, Zhiyu Huang, Luo Fang, (unknown), Lei Gong, Haifeng Yu, Haiyan Yang, (unknown), Weimin Mao	34
12	[Effect of miRNA-106a expression on the prognosis of patients with esophageal squamous cell carcinoma]. 2013 ·PubMed ·(unknown), Weimin Mao, Jun Luo, (unknown), Zhiguo Zheng, Zhi‐Qiang Ling	2
13	Methylenetetrahydrofolate reductase C677T polymorphism predicts response and time to progression to gemcitabine-based chemotherapy for advanced non-small cell lung cancer in a Chinese Han population 2013 ·Journal of Zhejiang University SCIENCE B ·Wei Hong, Kai Wang, Yiping Zhang, (unknown), (unknown), Dan Su, Weimin Mao, Xinmin Yu, Fajun Xie, Xiaojian Wang	18
14	DNA methylation of E-cadherin and Ras association domain family 1A in peripheral blood and tumor tissue in patients with esophageal squamous cell carcinoma 2012 ·Zhonghua shiyan waike zazhi ·Weimin Mao, Zhi‐Qiang Ling	1
15	Role of epidermal growth factor receptor tyrosine kinase inhibitors in the treatment of esophageal carcinoma and the suggested mechanisms of action 2012 ·Oncology Letters ·Yaping Xu, Liming Sheng, Weimin Mao	6
16	Expression and mutation of the c-kit gene and correlation with prognosis of small cell lung cancer 2012 ·Oncology Letters ·Hongyang Lu, (unknown), (unknown), Bo Chen, (unknown), Xiaojia Wang, Yiping Zhang, Zeng Wang, (unknown), Fajun Xie, Weimin Mao	29
17	[DNA methylation status of RARβ2 and p16(INK4α) in peripheral blood and tumor tissue in patients with esophageal squamous cell carcinoma]. 2012 ·PubMed ·Changchun Wang, Weimin Mao, Zhi‐Qiang Ling	6
18	Hypermethylation-modulated Downregulation of RASSF1A Expression Is Associated with the Progression of Esophageal Cancer 2011 ·Archives of Medical Research ·Weimin Mao, Pei Li, (unknown), Changchun Wang, Minghua Ge, (unknown), (unknown), (unknown), Zhi‐Qiang Ling	13
19	Primary Study of Lymph Node Metastasis‐Related Serum Biomarkers in Breast Cancer 2011 ·The Anatomical Record ·Liang Wang, Dan Su, (unknown), Jianhua Xu, Zhiguo Zheng, Yan‐Jun Hu, (unknown), Xiaowen Ding, Chun Chen, Bin Chen, Weimin Mao, (unknown)	6
20	Initiation of malignancy by duodenal contents reflux and the role of ezrin in developing esophageal squamous cell carcinoma 2009 ·Cancer Science ·Zhi‐Qiang Ling, Ken‐ichi Mukaisho, Hiroto Yamamoto, Kuan‐Hao Chen, Shinji Asano, Yoshio Araki, Hiroyuki Sugihara, Weimin Mao, Takanori Hattori	17

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact